Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock

Clin Res Cardiol. 2017 May;106(5):379-385. doi: 10.1007/s00392-016-1068-8. Epub 2017 Jan 16.

Abstract

Background: The current study presents data from a real-world cohort of patients with refractory cardiogenic shock (CS) undergoing extracorporeal life support (ECLS) focusing on the comparison of elderly versus younger patients.

Methods and results: One hundred consecutive patients with refractory CS underwent percutaneous ECLS implantation performed by interventional cardiologists. Follow-up was performed at hospital discharge as well as at a median of 18 months [interquartile range 15-36]. Patients were grouped according to median age (≤60 versus >60 years). ECLS could be weaned in more than half of the cohort (n = 56, 56%) with no differences between the age groups (p = 1.00). Despite similar rates of initial haemodynamic stabilisation, in-hospital mortality was higher in patients >60 years (82% versus 58%, p = 0.02). At mid-term follow-up, only three patients were alive in the group of patients >60 years. This resulted in a mortality rate of 94% in the elderly in comparison with 68% in patients aged ≤60 years (p = 0.001).

Conclusions: Despite a high rate of initial successful ECLS weaning, mid-term prognosis of patients with CS undergoing ECLS above the age of 60 years is poor with superior results in patients aged ≤60 years.

Keywords: Active support device; Age; Extracorporeal life support; Prognosis; Refractory cardiogenic shock.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Age Distribution
  • Aged
  • Chronic Disease
  • Extracorporeal Membrane Oxygenation / mortality*
  • Extracorporeal Membrane Oxygenation / statistics & numerical data*
  • Female
  • Germany / epidemiology
  • Hospital Mortality*
  • Humans
  • Incidence
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prevalence
  • Prognosis
  • Risk Factors
  • Shock, Cardiogenic / mortality*
  • Shock, Cardiogenic / therapy*
  • Survival Rate
  • Treatment Outcome